Home LiteratureArticle Details
PMID: 19230157 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Immunogenetics of seasonal influenza vaccine response.

Vaccine ·Vol. 26 Suppl 4 ·2008-09-12 ·Pages D35-40

Poland GA, Ovsyannikova IG, Jacobson RM

Abstract

Seasonal influenza causes significant morbidity, mortality, and economic costs. Vaccines against influenza, though both safe and effective, are imperfect. Notably, these vaccines result in significant immune response variability across the population. The mechanism for this variability, in part, appears to lie in the polymorphisms of key immune response genes. Despite the importance of this variability, little in the way of genetic polymorphisms and its association with vaccine immune response to viral vaccines has been performed. Herein, we review and synthesize what is known about the immune response pathway and influenza viral immunity and then present original data from our laboratory on the immunogenetic relationships between HLA, cytokine and cytokine receptor gene polymorphisms and the variations in humoral immune response to inactivated seasonal influenza vaccine. Finally, we propose that a better understanding of vaccine immunogenetics offers insight towards the development of better influenza vaccines.

MeSH Terms
Antibody Formation/genetics Genes, MHC Class II Humans Immunity, Cellular/genetics Influenza Vaccines/immunology Influenza, Human/prevention & control Polymorphism, Genetic
Chemicals
Influenza Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Poland Gregory A
Mayo Vaccine Research Group, The Program in Translational Immunovirology and Biodefense, Mayo Clinic, 611C Guggenheim Building, 200 First Street, SW, Rochester, MN 55905, USA. poland.gregory@mayo.edu
Ovsyannikova Inna G
Jacobson Robert M
References (50)
50 references, click to expand
  1. The association of class I HLA alleles and antibody levels after a single dose of measles vaccine.
    Hum Immunol. 2003 Jan;64(1):103-9 PMID: 12507820
  2. Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine.
    J Infect Dis. 2007 Oct 1;196(7):1021-5 PMID: 17763324
  3. Influenza vaccines: present and future.
    J Clin Invest. 2002 Jul;110(1):9-13 PMID: 12093881
  4. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.
    J Infect Dis. 2005 Feb 15;191(4):515-9 PMID: 15655774
  5. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed.
    J Endotoxin Res. 2004;10(4):201-22 PMID: 15373964
  6. Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells.
    J Immunol. 2007 Mar 15;178(6):3368-72 PMID: 17339430
  7. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia.
    Immunity. 1998 Jun;8(6):683-91 PMID: 9655482
  8. Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases.
    Vaccine. 2000 Aug 1;18(28):3280-6 PMID: 10869773
  9. T-cell memory and recall responses to respiratory virus infections.
    Immunol Rev. 2006 Jun;211:119-32 PMID: 16824122
  10. The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun.
    Vaccine. 2006 May 22;24(21):4471-4 PMID: 16140432
  11. Identification of an association between HLA class II alleles and low antibody levels after measles immunization.
    Vaccine. 2001 Nov 12;20(3-4):430-8 PMID: 11672906
  12. The IL-1 family and inflammatory diseases.
    Clin Exp Rheumatol. 2002 Sep-Oct;20(5 Suppl 27):S1-13 PMID: 14989423
  13. HLA antigens and the response to influenza A virus.
    Vox Sang. 1979;37(4):201-8 PMID: 494590
  14. IL-6 is a potent cofactor of IL-1 in IgM synthesis and of IL-5 in IgA synthesis.
    J Immunol. 1989 Oct 1;143(7):2230-5 PMID: 2789259
  15. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
    Virus Res. 2004 Jul;103(1-2):163-71 PMID: 15163505
  16. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep. 2006 Jul 28;55(RR-10):1-42 PMID: 16874296
  17. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses.
    Mol Cell. 2006 Jun 9;22(5):561-9 PMID: 16762830
  18. Human genes and influenza.
    J Infect Dis. 2008 Jan 1;197(1):1-3 PMID: 18171276
  19. A question of self-preservation: immunopathology in influenza virus infection.
    Immunol Cell Biol. 2007 Feb-Mar;85(2):85-92 PMID: 17213831
  20. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    J Infect Dis. 2000 Mar;181(3):1133-7 PMID: 10720541
  21. Serum antibodies against circulating influenza strains among vaccinated and unvaccinated general practitioners during two consecutive years (2002-2003).
    Vaccine. 2006 Apr 12;24(16):3145-52 PMID: 16490288
  22. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses.
    J Med Virol. 2001 Jul;64(3):262-8 PMID: 11424113
  23. Evidence for a heritable predisposition to death due to influenza.
    J Infect Dis. 2008 Jan 1;197(1):18-24 PMID: 18171280
  24. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics.
    Clin Pharmacol Ther. 2007 Dec;82(6):653-64 PMID: 17971814
  25. HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination.
    J Immunol. 2003 Sep 15;171(6):3163-9 PMID: 12960344
  26. Influenza: quantifying morbidity and mortality.
    Am J Med. 1987 Jun 19;82(6A):20-5 PMID: 3591814
  27. Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination.
    Rejuvenation Res. 2007 Mar;10(1):5-17 PMID: 17378748
  28. Association of HLA in immune response to influenza-A immunization.
    Transplant Proc. 1979 Dec;11(4):1849-52 PMID: 394432
  29. Human genetics and responses to influenza vaccination: clinical implications.
    Am J Pharmacogenomics. 2004;4(5):293-8 PMID: 15462607
  30. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza.
    Emerg Infect Dis. 2008 Jan;14(1):121-8 PMID: 18258091
  31. Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities.
    Int Immunol. 1998 Feb;10(2):211-22 PMID: 9533449
  32. Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling.
    J Transl Med. 2003 Nov 18;1(1):8 PMID: 14624696
  33. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules.
    Immunol Rev. 1996 Jun;151:5-30 PMID: 8872483
  34. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation.
    Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13980-5 PMID: 16172378
  35. HL-A antigens and antibody response after influenza A vaccination. Decreased response associated with HL-A type W16.
    N Engl J Med. 1976 Jan 1;294(1):13-6 PMID: 1105178
  36. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization.
    Nat Immunol. 2000 Oct;1(4):305-10 PMID: 11017101
  37. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine.
    Pediatrics. 2008 May;121(5):e1091-9 PMID: 18450852
  38. Host factors and susceptibility to influenza A infection: the effect of ABO blood groups and HL-A antigens.
    Dev Biol Stand. 1977 Jun 1-3;39:355-62 PMID: 604120
  39. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment.
    J Infect Dis. 1999 Sep;180(3):586-93 PMID: 10438343
  40. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination.
    J Immunol. 2007 Oct 1;179(7):4711-20 PMID: 17878370
  41. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population.
    Vaccine. 2006 Mar 6;24(10):1609-14 PMID: 16260072
  42. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines.
    Microbes Infect. 2006 Jul;8(8):2138-44 PMID: 16782388
  43. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine.
    J Infect Dis. 2002 Jan 1;185(1):114-7 PMID: 11756990
  44. Immune responses to killed influenza vaccine in patients with type 1 diabetes: altered responses associated with HLA-DR 3 and DR 4.
    J Lab Clin Med. 1988 Nov;112(5):595-602 PMID: 3263455
  45. Influenza virus evades innate and adaptive immunity via the NS1 protein.
    J Virol. 2006 Jul;80(13):6295-304 PMID: 16775317
  46. Therapeutics and toxicology.
    Curr Opin Pediatr. 1998 Apr;10(2):201-2 PMID: 9608900
  47. The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells.
    J Virol. 2007 Sep;81(17):9469-80 PMID: 17596305
  48. Novel mechanism of immunosuppression by influenza virus haemagglutinin: selective suppression of interleukin 12 p35 transcription in murine bone marrow-derived dendritic cells.
    J Gen Virol. 2005 Jul;86(Pt 7):1885-1890 PMID: 15958666
  49. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.
    Scand J Immunol. 2004 Jan;59(1):1-15 PMID: 14723616
  50. T cell responses are better correlates of vaccine protection in the elderly.
    J Immunol. 2006 May 15;176(10):6333-9 PMID: 16670345
Article Info
Journal
Vaccine
Abbr.
Vaccine
ISSN
0264-410X
DOI
10.1016/j.vaccine.2008.07.065
Email
poland.gregory@mayo.edu
Published
2008-09-12
Pages
D35-40
Language
English
Region
Netherlands
NLM ID
8406899
PMCID
PMC2610683
Subset
IM
Grants
NIAID NIH HHS · N01 AI400064 · United States
NIAID NIH HHS · R01 AI048793-08 · United States
NIAID NIH HHS · N01AI40065 · United States
NIAID NIH HHS · R01 AI048793 · United States
NIAID NIH HHS · R01 AI033144-14A2 · United States
NIAID NIH HHS · R37 AI048793 · United States
NIAID NIH HHS · AI 48793 · United States
NIAID NIH HHS · AI 33144 · United States
NCPDCID CDC HHS · U19 CI000407 · United States
NIAID NIH HHS · R01 AI033144 · United States
External Links
PubMed source DOI: 10.1016/j.vaccine.2008.07.065 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2